TP53 mutations (TP53mut) are observed in 5–13% of de novo myelodysplastic syndrome (MDS) [1–6] and 8–11% of acute myeloid leukemia (AML) cases [7, 8]. This evidence concerns the gene TP53 and myelodysplastic syndrome.